Adderall tablets, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg had a market value of roughly $421.7 million for the 12 months ending February 2025, per IQVIA.

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets (mixed ...

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc., will launch a bioequivalent version of Adderall tablets in strengths ranging from 5 mg to 30 mg, with distribution set to ...

Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 ...

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets ...

According to IQVIA™ sales data for the 12-month period ending February 2025, the Adderall® Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market [3] achieved annual sales of approximately $421.7 ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch [1] of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine ...

Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg ...

MAHWAH, N.J., April 16, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch[1] of Dextroamphetamine Saccharate, Amphetamine Aspartate ...